30-60岁新诊断糖尿病成人肺炎球菌疫苗接种的成本影响
本研究利用商业保险理赔数据,分析2005-2014年新诊断糖尿病的非老年成人及无糖尿病成人,评估肺炎球菌多糖疫苗接种率及接种与肺炎球菌疾病费用的关系。结果显示接种率低但上升,接种可能降低人均年费用90.54美元(95%CI: 183.59至-2.49,P=0.056)。
要点
- 30-60岁成人肺炎球菌多糖疫苗接种率低于1%/年,糖尿病患者接种率较高。
- 糖尿病患者接种率从2005年2.9%/年升至2014年6.0%/年。
- 接种可能降低人均年肺炎球菌疾病费用90.54美元,但置信区间跨零。
核心结论
- 非老年糖尿病患者肺炎球菌多糖疫苗接种率低但呈上升趋势,接种对减少肺炎球菌疾病总费用有适度影响。
研究设计与样本
- 基于商业保险理赔数据集的队列研究,纳入2005-2014年新诊断糖尿病的非老年成人及无糖尿病成人,比较接种率及接种与肺炎球菌疾病费用的关系。
主要发现
- 30-60岁成人肺炎球菌多糖疫苗接种率总体低于1%/年,糖尿病患者接种率更高。
- 糖尿病患者中,与诊断同年接种者的接种率从2005年2.9%/年增至2014年6.0%/年。
- 在倾向评分匹配数据集上使用两部分双重差分模型,接种可能使糖尿病患者人均年肺炎球菌疾病费用降低90.54美元(95%CI: 183.59至-2.49,P=0.056)。
临床怎么用
- 应关注非老年糖尿病患者的肺炎球菌疫苗接种,尽管当前接种率低但正在改善。
- 接种对肺炎球菌疾病费用的影响适度,需结合成本效益综合评估。
局限性
- 研究基于商业保险理赔数据,可能不覆盖无保险人群。
- 接种对费用的影响置信区间跨零,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The 23-valent pneumococcal polysaccharide vaccine is routinely recommended for adults with diabetes, but little is known about adherence to this recommendation and how vaccination of these adults affects costs related to pneumococcal disease. RESEARCH DESIGN AND METHODS: We used data from a commercial insurance claims dataset to examine a cohort of non-elderly adults with a new diagnosis of diabetes and adults with no diagnosis of diabetes from 2005 to 2014. We examined rates of pneumococcal polysaccharide vaccination and the relationship between vaccination and pneumococcal disease costs, comparing results for persons with a diagnosis of diabetes and those with no diagnosis of diabetes. RESULTS: Overall rates of pneumococcal polysaccharide vaccination among adults 30-60 years old were <1%/year. Rates of pneumococcal polysaccharide vaccination were higher for adults with diabetes. Pneumococcal polysaccharide vaccination rates more than doubled from 2.9% per year in 2005 to 6.0% per year in 2014 for adults vaccinated during the same year as their diabetes diagnosis. Using a two-part differences-in-differences model on a propensity-score matched dataset, pneumococcal polysaccharide vaccination may reduce average annual per-person pneumococcal disease costs by $90.54 [95% CI: $183.59, -$2.49, (p = 0.056)] in persons with diabetes from two years before to two years after vaccination. CONCLUSIONS: Non-elderly adults with diabetes have low but rising rates of pneumococcal polysaccharide vaccination. Pneumococcal polysaccharide vaccination has a modest impact reducing overall costs of pneumococcal disease in this population.
引用
- Hutton DW, McCullough JS, Prosser L, et al. Costs implications of pneumococcal vaccination of adults aged 30-60 with a recent diagnosis of diabetes. Vaccine. 2021. PMID: 33494965. doi:10.1016/j.vaccine.2020.11.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。